Deal volume was up 20 percent in the pharmaceutical and life sciences sector in the last 12 months as dealmakers grew more comfortable with uncertainty. Total deal value was roughly flat in the same period. All four subsectors saw an increase in deal volume, with pharma being the one subsector also experiencing an increase in deal value. Industry players have pivoted further and faster toward high-innovation areas with the potential to fill looming loss-of-exclusivity gaps in the latter half of the decade. PwC expects deal activity to remain strong in the second half of 2024 despite sustained headwinds.
Read the full article: PwC: Pharmaceutical and Life Sciences – US Deals 2024 Midyear Outlook //
Source: https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html